Evolent Health Stock Today
| EVH Stock | USD 30.30 0.04 0.13% |
Performance9 of 100
| Odds Of DistressLess than 11
|
Evolent Health is trading at 30.30 as of the 11th of September 2024. This is a 0.13 percent increase since the beginning of the trading day. The stock's open price was 30.26. Evolent Health has less than a 11 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Evolent Health are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of November 2022 and ending today, the 11th of September 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 5th of June 2015 | Category Healthcare | Classification Health Care |
Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. The company was founded in 2011 and is headquartered in Arlington, Virginia. The company has 116.29 M outstanding shares of which 15.87 M shares are currently shorted by investors with about 5.84 days to cover. More on Evolent Health
Moving together with Evolent Stock
Moving against Evolent Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Evolent Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Dan McCarthy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Technology, Health Care Equipment & Services, Health Care, NYSE Composite, Health Care, Health Care Technology, Health Information Services, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEvolent Health can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Evolent Health's financial leverage. It provides some insight into what part of Evolent Health's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evolent Health (EVH) is traded on New York Stock Exchange in USA. It is located in 1812 N. Moore Street, Arlington, VA, United States, 22209 and employs 4,700 people. Evolent Health is listed under Health Care Technology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 3.52 B. Evolent Health runs under Health Care Technology sector within Health Care industry. The entity has 116.29 M outstanding shares of which 15.87 M shares are currently shorted by investors with about 5.84 days to cover.
Evolent Health has about 188.2 M in cash with 142.58 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.57.
Check Evolent Health Probability Of Bankruptcy
Ownership AllocationThe majority of Evolent Health outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Evolent Health to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Evolent Health. Please pay attention to any change in the institutional holdings of Evolent Health as this could imply that something significant has changed or is about to change at the company.
Check Evolent Ownership Details
Evolent Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Holocene Advisors, Lp | 2024-06-30 | 3.1 M | |
| Granahan Investment Management Inc.. | 2024-06-30 | 3 M | |
| State Street Corp | 2024-06-30 | 2.7 M | |
| Orbimed Advisors, Llc | 2024-06-30 | 2.6 M | |
| Geode Capital Management, Llc | 2024-06-30 | 2.6 M | |
| Dimensional Fund Advisors, Inc. | 2.4 M | ||
| Bank Of New York Mellon Corp | 2024-06-30 | 2 M | |
| Bellevue Group Ag | 2024-06-30 | 1.7 M | |
| Hood River Capital Management Llc | 2024-06-30 | 1.6 M | |
| Wellington Management Company Llp | 2024-06-30 | 11.2 M | |
| Vanguard Group Inc | 2024-06-30 | 11.1 M |
Evolent Health Historical Income Statement
Evolent Stock Against Markets
Evolent Health Corporate Directors
| Bridget Duffy | Independent Director | Profile | |
| Bruce Felt | Independent Director | Profile | |
| Cheryl Scott | Lead Independent Director | Profile | |
| David Farner | Director | Profile |
Additional Information and Resources on Investing in Evolent Stock
When determining whether Evolent Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evolent Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evolent Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evolent Health Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolent Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Evolent Stock please use our How to Invest in Evolent Health guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolent Health. If investors know Evolent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolent Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 20.705 | Quarterly Revenue Growth 0.379 | Return On Assets 0.01 | Return On Equity (0.06) |
The market value of Evolent Health is measured differently than its book value, which is the value of Evolent that is recorded on the company's balance sheet. Investors also form their own opinion of Evolent Health's value that differs from its market value or its book value, called intrinsic value, which is Evolent Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolent Health's market value can be influenced by many factors that don't directly affect Evolent Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolent Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolent Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolent Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.